secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124436
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports Q3 2024 net loss of $8.7M; cash runway through end of 2025; topline data expected Dec 2024
--------------------------------------------------------------------------------

- Net loss of $8.7M in Q3 2024 ($29.5M nine months); cash and equivalents $60.1M as of Sept 30, 2024.
- R&D expenses fell to $6.6M (Q3 2024) from $13.5M (Q3 2023) due to study terminations and completions.
- Collaboration revenue of $0.6M in Q3 2024 vs $3.1M a year ago, from Kaken Pharmaceutical partnership.
- Topline results from CAHmelia-204 (adult CAH) and CAHptain-205 (adult & pediatric CAH) trials expected December 2024.
- End-of-Phase 2 meeting with FDA for tildacerfont anticipated in first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/0000950170-24-124436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/sprb-20241111.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer